EGFR and non-small cell lung carcinoma: In conclusion, ICI therapy, especially front-line ICI therapy and ICI-based combination therapy, may be beneficial for improving the prognosis of advanced EGFR-mutant NSCLC patients after EGFR-TKI therapy discontinuation.